Business Wire

Teva Pharmaceuticals Europe: Patients Search for Information Online – but Aren’t Sure If They Can Trust What They Find

Del

Recent research commissioned1 by Teva Pharmaceuticals has shown that patients, especially those with chronic conditions, have a significant need for online information but they question the reliability of some sources.1

Today, Teva in Europe announced a series of partnerships and initiatives aimed at directly addressing this unmet need. The first, a partnership with Healint, the developer of the Migraine Buddy© platform, will provide real-world evidence about the many issues and outcomes experienced by migraine patients in Europe. These statistical insights produced by Healint on their platform are based on the contributions of patients, who opt-in to share about their condition anonymously for the purpose of increased migraine awareness, and research. This patient-reported evidence with an unprecedented scale will support the generation of educational and supportive content for doctors, neurologists, health specialists and individuals looking to enhance their understanding of migraine.

Recent research in the professional field highlights the growing interest by medical professionals in digital assets to support their continuous education needs and day-to-day work. A 2017 DRG Digital report found that millennial physicians are more reliant on digital sources of information spending as much as three hours consulting external digital resources including websites for healthcare professionals. They source online medical journals and medical reference sites far more frequently than their older peers.2

To address this professional need Teva is working with Migraine Trust International Symposium (MTIS) to create engaging online interviews with leaders in the field of neurology including Professor of Neurology at King's College London and Medical Trustee of The Migraine Trust, Peter J. Goadsby on the subject of ‘Recent advances in headache neuroimaging’. These videos and content will be made available through the MTIS website for UK delegates and on NeurologyBytes.com for non-UK delegates.

Neurology Bytes is a European Healthcare Professional portal initiated by Teva Europe that hosts a variety of educational content that complements the busy schedule of a neurologist and addresses the unmet need for reliable and trustworthy information.

CEO and Co-Founder of Healint, Francois Cadiou commends Teva’s efforts to provide independently reviewed information to support healthcare professionals in becoming more knowledgeable about migraine. “Our collaboration with Teva aims to support healthcare professionals to understand migraine patients better, so that they can obtain the most effective care plan faster. We at Healint are happy to support this transformative initiative with the unique data analysis carried out on the Healint platform. This fact-based information and our collaboration with Teva provides significant benefits to the entire migraine community.”

Professor of Neurology at King's College London and Medical Trustee of The Migraine Trust, Peter J. Goadsby MD PhD stated: “Migraine is a complex condition which requires broader disease awareness in order for patients to communicate effectively about their condition. Patients often need to be their own advocates given the significant amount of patient information doctors require to diagnose and treat their conditions. I welcome Teva’s initiatives which aim to support both the patient and the medical community through reliable and trustworthy information. I hope this initiative creates a better dialogue between patients and their doctors so they can determine the best course of treatment for this debilitating condition.”

Teva Head of Digital, Timothy White said: “Teva is committed to empowering patients and professionals around the world through their health journey, especially those living with or treating chronic conditions such as migraine, by providing high quality medicines as well as tools based on human insights. Our partnerships with MTIS and Healint as well as the growth of our Neurologybytes.com platform demonstrate the practical ways of how we are bringing the vision to life.”

-ENDS-

About the Research

The research (2018) found:

  • 7 in 10 people (73%) in the UK have a chronic condition and online resources continue to be sought with over half (58%) of UK respondents with chronic conditions claiming to have searched for information on a weekly or monthly basis1
  • People living with chronic conditions were more likely to search for health information online on a weekly or monthly basis (58%) compared to those without chronic conditions (44%)1
  • The biggest issue that the UK faces in relation to online health information is understanding if it is trustworthy and reliable1
  • Search engines are the most popular online source of health information but not the most trusted. For example, in the UK, the NHS Choices website is the most trusted source of information with 3 out of 4 (75%) of respondents stating they trust the site to have quality and dependable information1

About Migraine

Migraine is an unpredictable neurological condition with symptoms such as severe head pain and physical impairment that can impact quality of life and productivity.3 There are two clinical manifestations of migraine – chronic, where patients suffer 15 or more headache days per month, and episodic, where patients have 14 or less headache days per month.4 With more than 1 billion people affected worldwide, migraine is the third most prevalent illness in the world.3

References

1. Edelman Intelligence 2018. Teva Brand Research - UK information

2. Meet the Millennial Physicians – Young, Mobile, and Harder to Reach. DRG Digital. Available at: https://www.drgdigital.com/drg-digital-innovation-blog/meet-the-millennial-physicians-young-mobile-and-harder-to-reach. Accessed 31.08.18

3. Migraine Research Foundation, Migraine Facts. Available at: http://migraineresearchfoundation.org/about-migraine/migraine-facts/. Accessed 31.08.18

4. Adapted from American Migraine Foundation. Available at: https://americanmigrainefoundation.org/understanding-migraine/chronic-migraine/. Accessed 31.08.18

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 45,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com.

About Healint

Healint helps the one billion people who suffer from migraine and other neurological conditions and is the developer of the world’s largest migraine tracking and research platform Migraine Buddy©. With more than one million registered users and 100 million migraine days tracked on the platform, Migraine Buddy© is the most popular condition-specific app in the world, and a Top 10 medical app in the USA and Europe. Using deep analytics and machine learning, Healint generates real-world evidence for patients, physicians, and researchers to improve treatment outcomes and expedite clinical trials. Healint collaborates with the world's leading scientists to improve the diagnosis, treatment, and lives of patients suffering from multiple neurological conditions. For more information, visit: www.healint.com.

###

Date of Preparation: September 2018 | Ref: UK/CPE/18/0065

Contact information

Teva Pharmaceuticals
Fiona Cohen
+ 31 6 2008 2545
Fiona.Cohen@Tevaeu.com
or
Healint
Susanna Hasenoehrl
susanna@healint.com
+65 8657 9176

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Process Systems Enterprise: gPROMS FormulatedProducts 1.4 Includes Enhanced Capabilities Linking Digital Design to Digital Operations19.4.2019 07:58:00 CESTPressemelding

Process Systems Enterprise (PSE), the Advanced Process Modelling company, today released version 1.4 of gPROMS FormulatedProducts, the mechanistic model-based environment for integrated digital design of robust formulated products and their manufacturing processes, and related digital process operation. This release introduces major enhancements to both the gPROMS FormulatedProducts model libraries and the underlying gPROMS platform 6.0, including morphological crystallizer and sensor models to capture particle size and shape evolution, enhanced continuous direct compression models and improved wet granulation models. Platform enhancements include support for cluster computing, to significantly speed up execution of parameter estimation and other complex numerical solutions, and comprehensive global system analysis of dynamic systems for rapid exploration of the time-varying decision space and systematic risk and uncertainty analysis. Version 1.4 also introduces two key usability enhan

LOXAM Contributes to the Reconstruction of Notre Dame De Paris Cathedral19.4.2019 07:44:00 CESTPressemelding

In the wake of the Notre Dame de Paris blaze on Monday 15 April, Loxam the leading equipment rental company in Europe is playing its part in the reconstruction project of the partly destroyed cathedral. A rental operator in the construction equipment, LOXAM pledges to provide, free of charge, machines to the companies and tradesmen who will take part in these restoration works for the scheduled duration of five years. “Notre Dame de Paris Cathedral is the legacy of accomplished builders that we ought to preserve. As a committed rental operator, Loxam wishes to contribute to the rehabilitation of this monument by providing equipment for an overall 10-million € value over the upcoming five years” Gérard DEPREZ, President of LOXAM, indicates. With a fleet of over 200,000 machines, Loxam is meeting the needs of all tradesmen operating on this worksite. View source version on businesswire.com: https://www.businesswire.com/news/home/20190419005025/en/ Contact information PRESS : Virginie Ada

IFF to Release First Quarter 2019 Results May 618.4.2019 20:15:00 CESTPressemelding

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of scent, taste, and nutrition, announced that it will release its first quarter 2019 earnings results following the market close on Monday, May 6, 2019. The management team will host a live webcast on Tuesday, May 7, 2019 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF) is a leading innovator of scent, taste, and nutrition, with 97 manufacturing facilities, 105 R&D centers, and 39,000 customers globally. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration dri

Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 201918.4.2019 20:05:00 CESTPressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2019 financial results will be released on Thursday, May 2, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the first quarter 2019 and provide a business update. The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 5259422 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, May 4, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the conference ID

Andersen Global Expands Africa Presence; Signs Collaboration Agreement in Economic Hub of South Africa18.4.2019 13:30:00 CESTPressemelding

Andersen Global is excited to announce the addition of its first collaborating firm in South Africa. Tabacks Attorneys and Corporate Law Advisors, headquartered in Johannesburg, South Africa, has signed a Collaboration Agreement with Andersen Global, an international association of member and collaborating firms. South Africa marks the tenth country in Africa in which Andersen Global has a presence. Led by Chairman David Woodhouse, Tabacks has a team of 27 lawyers who offer legal assistance and commercial advice to a diverse clientele in construction, manufacturing, energy, mining, explosives, retail, hospitality, logistics, pharmaceutical, property and banking industries. The firm is considered a leading law firm in South Africa, and its practice areas include competition law, commercial law, mining, employment law, environmental health & safety law, tax and litigation. “The global economy is rapidly changing, which brings unique challenges to corporate and commercial law,” said David

Amazon and Google Announce Official YouTube Apps to Launch on Fire TV; Prime Video App Coming to Chromecast and Android TV18.4.2019 13:00:00 CESTPressemelding

Today, Amazon (NASDAQ: AMZN) and Google (NASDAQ: GOOGL) announced that in the coming months, the two companies will launch the official YouTube app on Amazon Fire TV devices and Fire TV Edition smart TVs, as well as the Prime Video app for streaming to Chromecast and Chromecast built-in devices. In addition, Prime Video will be broadly available across Android TV device partners, and the YouTube TV and YouTube Kids apps will also come to Fire TV later this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005212/en/ “We are excited to work with Amazon to launch the official YouTube apps on Fire TV devices worldwide,” said Heather Rivera, Global Head of Product Partnerships at YouTube. “Bringing our flagship YouTube experience to Amazon Fire TV gives our users even more ways to watch the videos and creators they love.” “We’re excited to bring the Prime Video app to Chromecast and Android TV devices, and to give our c